BRCA2 and breast cancer: A similar observation was recently reported in a meta-analysis by Baretta and colleagues, showing decreased BC-specific survival (HR = 1.42 95% CI 1.05–1.92) but non-significantly changed DFS for BRCA1/BRCA2 mutation carriers [18].